SNDX
Syndax Pharmaceuticals Inc
Key Financials
Net Income
$-285422000
↑ 10.5%
Revenue
$172.4M
↑ 627.8%
Operating Income
$-273084000
↑ 19.6%
EPS (Diluted)
$-3.29
↑ 11.6%
Total Assets
$529.7M
↓ 26.9%
Total Liabilities
$465.1M
↑ 6.5%
Shareholders' Equity
$64.6M
↓ 77.6%
Cash & Equivalents
$134.9M
↓ 12.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| S-8 | 2/26/2026 | View on SEC |
| 10-K | 2/26/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| 4 | 2/10/2026 | View on SEC |
| 4 | 2/10/2026 | View on SEC |
| 144 | 2/9/2026 | View on SEC |
| 144 | 2/9/2026 | View on SEC |
| SCHEDULE 13G | 2/9/2026 | View on SEC |
| 4 | 2/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SNDX |
| Company Name | Syndax Pharmaceuticals Inc |
| CIK | 1395937 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 781-419-1400 |